OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs
WALTHAM, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced the appointment of Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs.
“I am thrilled to reunite with Colleen and have her join our team given her deep expertise in oncology drug development,” said Laura Benjamin, Ph.D., President and Chief Executive Officer at OncXerna Therapeutics. “Her track record of success in developing and executing clinical development and regulatory strategies is impressive. This track record will be critical as we prepare to advance our navicixizumab and bavituximab programs towards registration trials using our unique RNA-base
A recent market study published by the company “Chemotherapy-Induced Myelosuppression Treatment Market: Global Industry Analysis 2013–2017 & Opportunity Assessment 2018–2028” consists of a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historic as well as cu.
Chemotherapy Induced Myelosuppression Treatment Market to Witness a Pronounce Growth During 2018-2028 marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.